NAB2, a corepressor of EGR-1, inhibits vascular endothelial growth factor-mediated gene induction and angiogenic responses of endothelial cells - PubMed (original) (raw)
. 2003 Mar 28;278(13):11433-40.
doi: 10.1074/jbc.M204937200. Epub 2002 Nov 8.
Diana Mechtcheriakova, Alexandra Kadl, Gernot Schabbauer, Romana Schäfer, Florian Gruber, Yuri Koshelnick, Horst-Dietmar Müller, Katja Issbrücker, Matthias Clauss, Bernd R Binder, Erhard Hofer
Affiliations
- PMID: 12427750
- DOI: 10.1074/jbc.M204937200
Free article
NAB2, a corepressor of EGR-1, inhibits vascular endothelial growth factor-mediated gene induction and angiogenic responses of endothelial cells
Markus Lucerna et al. J Biol Chem. 2003.
Free article
Abstract
In this study we have investigated the role of a specific corepressor of EGR-1, NAB2, to down-regulate vascular endothelial growth factor (VEGF)-induced gene expression in endothelial cells and to inhibit angiogenesis. Firstly, we show a reciprocal regulation of EGR-1 and NAB2 following VEGF treatment. During the initial phase EGR-1 is rapidly induced and NAB2 levels are down-regulated. This is followed by a reduction of EGR-1 and a concomitant increase of NAB2. Secondly, using the tissue factor gene as a readout for VEGF-induced and EGR-1-regulated gene expression we demonstrate that NAB2 can completely block VEGF-induced tissue factor reporter gene activity. Thirdly, by adenovirus-mediated expression we show that NAB2 inhibits up-regulation of tissue factor, VEGF receptor-1, and urokinase plasminogen activator mRNAs even when a combination of VEGF and bFGF is used for induction. In addition, NAB2 overexpression significantly reduced tubule and sprout formation in two different in vitro angiogenesis assays and largely prevented the invasion of cells and formation of vessel-like structures in the murine Matrigel model. These data suggest that NAB2 regulation represents a mechanism to guarantee transient EGR-1 activity following exposure of endothelial cells to VEGF and that NAB2 overexpression could be used to inhibit signals involved in the early phase of angiogenesis.
Similar articles
- Functional role of Egr-1 mediating VEGF-induced tissue factor expression in the retinal capillary endothelium.
Sassa Y, Hata Y, Murata T, Yamanaka I, Honda M, Hisatomi T, Fujisawa K, Sakamoto T, Kubota T, Nakagawa K, Sueishi K, Ishibashi T. Sassa Y, et al. Graefes Arch Clin Exp Ophthalmol. 2002 Dec;240(12):1003-10. doi: 10.1007/s00417-002-0576-6. Epub 2002 Nov 6. Graefes Arch Clin Exp Ophthalmol. 2002. PMID: 12483323 - Stromal cell-derived factor 1alpha (SDF-1alpha) induces gene-expression of early growth response-1 (Egr-1) and VEGF in human arterial endothelial cells and enhances VEGF induced cell proliferation.
Neuhaus T, Stier S, Totzke G, Gruenewald E, Fronhoffs S, Sachinidis A, Vetter H, Ko YD. Neuhaus T, et al. Cell Prolif. 2003 Apr;36(2):75-86. doi: 10.1046/j.1365-2184.2003.00262.x. Cell Prolif. 2003. PMID: 12680875 Free PMC article. - Specificity, diversity, and convergence in VEGF and TNF-alpha signaling events leading to tissue factor up-regulation via EGR-1 in endothelial cells.
Mechtcheriakova D, Schabbauer G, Lucerna M, Clauss M, De Martin R, Binder BR, Hofer E. Mechtcheriakova D, et al. FASEB J. 2001 Jan;15(1):230-242. doi: 10.1096/fj.00-0247com. FASEB J. 2001. PMID: 11149911 - Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.
Shinkaruk S, Bayle M, Laïn G, Déléris G. Shinkaruk S, et al. Curr Med Chem Anticancer Agents. 2003 Mar;3(2):95-117. doi: 10.2174/1568011033353452. Curr Med Chem Anticancer Agents. 2003. PMID: 12678905 Review. - Signals and genes induced by angiogenic growth factors in comparison to inflammatory cytokines in endothelial cells.
Schweighofer B, Schultes J, Pomyje J, Hofer E. Schweighofer B, et al. Clin Hemorheol Microcirc. 2007;37(1-2):57-62. Clin Hemorheol Microcirc. 2007. PMID: 17641395 Free PMC article. Review.
Cited by
- PTPN2 copper-sensing relays copper level fluctuations into EGFR/CREB activation and associated CTR1 transcriptional repression.
Ross MO, Xie Y, Owyang RC, Ye C, Zbihley ONP, Lyu R, Wu T, Wang P, Karginova O, Olopade OI, Zhao M, He C. Ross MO, et al. Nat Commun. 2024 Aug 13;15(1):6947. doi: 10.1038/s41467-024-50524-5. Nat Commun. 2024. PMID: 39138174 Free PMC article. - Proteomic and Transcriptomic Landscapes of Alström and Bardet-Biedl Syndromes.
Smyczynska U, Stanczak M, Kuljanin M, Włodarczyk A, Stoczynska-Fidelus E, Taha J, Pawlik B, Borowiec M, Mancias JD, Mlynarski W, Rieske P, Fendler W, Zmysłowska A. Smyczynska U, et al. Genes (Basel). 2022 Dec 15;13(12):2370. doi: 10.3390/genes13122370. Genes (Basel). 2022. PMID: 36553637 Free PMC article. - A Comprehensive Review on Solitary Fibrous Tumor: New Insights for New Horizons.
Martin-Broto J, Mondaza-Hernandez JL, Moura DS, Hindi N. Martin-Broto J, et al. Cancers (Basel). 2021 Jun 10;13(12):2913. doi: 10.3390/cancers13122913. Cancers (Basel). 2021. PMID: 34200924 Free PMC article. Review. - EGR1 Addiction in Diffuse Large B-cell Lymphoma.
Kimpara S, Lu L, Hoang NM, Zhu F, Bates PD, Daenthanasanmak A, Zhang S, Yang DT, Kelm A, Liu Y, Li Y, Rosiejka A, Kondapelli A, Bebel S, Chen M, Waldmann TA, Capitini CM, Rui L. Kimpara S, et al. Mol Cancer Res. 2021 Aug;19(8):1258-1269. doi: 10.1158/1541-7786.MCR-21-0267. Epub 2021 May 12. Mol Cancer Res. 2021. PMID: 33980611 Free PMC article. - Clotting disorder in severe acute respiratory syndrome coronavirus 2.
Pujhari S, Paul S, Ahluwalia J, Rasgon JL. Pujhari S, et al. Rev Med Virol. 2021 May;31(3):e2177. doi: 10.1002/rmv.2177. Epub 2020 Oct 6. Rev Med Virol. 2021. PMID: 33022790 Free PMC article. Review.